Nasdaq
$0.1692▼ 10.43%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $179,879.40Shares out 1.1M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
53- 5d agoAfter-hours26.10.20 05:05DEFA14AOther#●●●#●●●
Silexion Therapeutics Corp
Silexion Therapeutics adjourned its extraordinary general meeting originally scheduled for October 19, 2026, to October 26, 2026. The meeting will address proposals to increase authorized share capital by 500 million shares and implement a reverse share split at a ratio between 1-for-15 and 1-for-25 to maintain Nasdaq listing compliance.…more
$0.1692-10.43%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 10.5After-hours26.10.06 05:09DEF 14AOther
Silexion Therapeutics Corp
Silexion Therapeutics will hold an extraordinary general meeting on October 19, 2026, to vote on increasing authorized share capital by 500 million shares and a reverse share split at a ratio of 1-for-15 to 1-for-25. The company is currently facing potential delisting from Nasdaq due to minimum bid price non-compliance and seeks these measures to restore compliance and secure financing flexibility for its clinical programs.…more
$0.1692-10.43%vs prev closeView filingShare - 9.30Pre-market26.09.30 21:528-KKey event
Silexion Therapeutics Corp
Silexion Therapeutics has successfully dosed the first patient in its Phase 2/3 clinical trial of SIL204 for locally advanced pancreatic cancer. The study is structured with an initial safety run-in cohort of approximately 18 patients, followed by a randomized expansion cohort of approximately 166 patients across clinical sites in Israel and Germany.…more
$0.1692-10.43%vs prev closeView filingShare
52 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 9.30Pre-market26.09.30 21:00#●●●#●●●#●●●
Silexion Therapeutics Doses First Patient in Phase 2/3 Trial of SIL204 for Pancreatic Cancer…more
Silexion Therapeutics has successfully dosed the first patient in its global Phase 2/3 clinical trial evaluating SIL204 for locally advanced pancreatic cancer. The study assesses the efficacy and safety of the drug in combination with standard chemotherapy, marking a key milestone in the company's clinical development program.…more
$0.1692-10.43%vs prev closeDetected5m · 30m · 60m · Next dayPLUS
- 9.29Pre-market26.09.29 21:03
●●●●●●●● ●●●●● ●●●●●●
Silexion Therapeutics has entered into agreements for the immediate exercise of existing warrants and the issuance of new Series F and G warrants to raise capital. This transaction involves potential share dilution, which investors should monitor closely.…more
$0.1692-10.43%vs prev close - 9.29Overnight26.09.29 15:29
●●●●●●●● ●●●●● ●●●●●●
Silexion Therapeutics reported positive preclinical findings for its KRAS-driven cancer therapy candidate, SIL204. As the company remains in the clinical stage without commercial revenue, investors should exercise caution regarding the long-term impact of these early-stage results.…more
$0.1692-10.43%vs prev closeShareBenzinga
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report